Apremilast for the treatment of refractory erythema multiforme

Recruiting

99 years and younger

All

Phase 2

8 participants needed

1 Location

Brief description of study

The research study is being conducted to help physicians understand if apremilast, an oral medication, is effective in treating recurrent oral erythema multiforme (EM). Study consists of four research study visits (weeks 0,6. 12, 24, 36) and completion of a daily treatment diary during the 24 week tratment period. Week 36 is a follow-up visit to access for safety and can be in person or by phone if subject cannot report to clinic Key eligibility criteria includes male and females age 18-89 years old with a diagnosis of oral, genital, or cutaneous erythema multiforme.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: - 99 Years
Gender: All

Updated on 01 Aug 2024. Study ID: 842831

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).